Yujie Wang

发表

Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial.

Haiwen Huang, Lindong Li, K. Zhou, 2024, Annals of hematology.